{"id":"sub-cutaneous-liraglutide","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–10","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"10–20","effect":"Constipation"},{"rate":"5–10","effect":"Headache"},{"rate":"5–15","effect":"Hypoglycemia (when combined with insulin or sulfonylureas)"}]},"_chembl":{"chemblId":"CHEMBL4084119","moleculeType":"Protein","molecularWeight":"3751.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also reduces glucagon secretion when blood glucose is elevated and delays gastric emptying, leading to reduced postprandial glucose excursions. These combined effects improve glycemic control in type 2 diabetes and promote modest weight loss.","oneSentence":"Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:07.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Weight management in obese or overweight patients"}]},"trialDetails":[{"nctId":"NCT02832999","phase":"PHASE4","title":"Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Victoza"],"phase":"marketed","status":"active","brandName":"sub cutaneous liraglutide","genericName":"sub cutaneous liraglutide","companyName":"Yaounde Central Hospital","companyId":"yaounde-central-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying. Used for Type 2 diabetes mellitus, Weight management in obese or overweight patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}